|
Friday, June 7, 2019 |
|
PromarkerD features at American Diabetes Association 79th Scientific Sessions saying diabetics deserve to know their future kidney disease status |
Proteomics International (ASX: PIQ) has been invited to feature on the American Diabetes Association (ADA) TV News Network as a key opinion leader (KOL) on diabetic kidney disease diagnostics, which includes an update on PromarkerD, during the ADA 79th Scientific Sessions conference in San Francisco, June 7-11, 2019. more info >> |
|
Monday, June 3, 2019 |
|
Proteomics International and PromarkerD at BIO 2019 saying 30 million diabetics in US deserve to know their future kidney disease status |
Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) will have a stand #2349 at the BIO International Convention (Philadelphia, June 3-6, 2019). more info >> |
|
Monday, June 4, 2018 |
|
Proteomics International signs with PrismHealthDx for US launch of PromarkerD predictive test for diabetic kidney disease |
Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) has signed the first licence agreement for its world-leading PromarkerD predictive test for diabetic kidney disease in the United States. more info >> |
|
Proteomics国际与PrismHealthDx 缔约在美国启动PromarkerD糖尿病肾脏疾病预测测试 |
医药技术公司Proteomics国际(Proteomics国际实验室有限公司;ASX: PIQ)已经与美国精密医疗和诊断服务实验室PrismHealthDx 股份有限公司(PHDx )签署了首个许可协议,联手在美国启动全球领先的PromarkerD糖尿病肾病预测测试。 more info >> |
|
Proteomics國際與PrismHealthDx 締約在美國啟動PromarkerD糖尿病腎臟疾病預測測試 |
醫藥技術公司Proteomics國際(Proteomics國際實驗室有限公司;ASX: PIQ)已經與美國精密醫療和診斷服務實驗室PrismHealthDx 股份有限公司( PHDx )簽署了首個許可協議,聯手在美國啟動全球領先的PromarkerD糖尿病腎病預測測試。 more info >> |
|
Tuesday, March 20, 2018 |
|
PromarkerD Diagnostic Test Leader Officially Launched |
Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) has announced the official product launch of its world leading predictive diagnostic test for diabetic kidney disease, "PromarkerD". more info >> |
|
Monday, February 12, 2018 |
|
Proteomics International announces Strategic Alliance and Investment in CPR Pharma Services |
MedTech pioneer Proteomics International (PILL; ASX: PIQ) has entered into a strategic alliance with CPR Pharma Services (CPR), targeting the high growth area of clinical trials and related research, with an offer to acquire 10% of CPR's share capital through the issue of 4 million PIQ shares. more info >> |
|
Monday, June 12, 2017 |
|
Clinical Validation Results confirm PromarkerD can predict Diabetic Kidney Disease better than any Current Measure |
Proteomics International Laboratories Ltd (ASX: PIQ) (PILL) announced today results from its validation clinical study showing that the PromarkerD blood test can predict the onset of diabetic kidney disease better than any current measure. more info >> |
|
Tuesday, March 28, 2017 |
|
Frost & Sullivan独立行业报告将PromarkerD确定为糖尿病肾脏疾病的领先诊断试验 |
依照本月发布的独立Frost & Sullivan报告,Proteomics International Laboratories Ltd (ASX:PIQ)(PILL) 成为糖尿病肾脏疾病的预测诊断的领导者。 more info >> |
|
Frost & Sullivan獨立行業報告將PromarkerD確定為糖尿病腎臟疾病的領先診斷試驗 |
依照本月發布的獨立Frost & Sullivan報告,Proteomics International Laboratories Ltd (PILL,ASX:PIQ)成為糖尿病腎臟疾病的預測診斷的領導者。 more info >> |
|
|
|